OBJECTIVES: To evaluate the association between histamine-2 receptor antagonist (H2A) exposure and incident cognitive impairment in a community-based sample of African Americans. DESIGN: Five-year longitudinal observational study. PARTICIPANTS: A sample of 1,558 community-dwelling African Americans aged 65 and older with no baseline cognitive impairment living in Indianapolis, Indiana. OUTCOME MEASURE: Incident cognitive impairment, defined as incident dementia, cognitive impairment without dementia, or poor cognitive performance, as determined using combined cognitive assessments that included the Community Screening Instrument for Dementia, a comprehensive clinical assessment including informant interview, and neuropsychological testing. EXPOSURE: Trained interviewers assessed the use of prescription and over-the-counter H2As using in-home inspection of medications and report of participants and informants. RESULTS: Incident cognitive impairment occurred in 275 (17.7%) participants. After controlling for age, education, baseline cognitive score, the use of anticholinergics, and history of diabetes mellitus and depression, continuous use of H2As was associated with greater risk of incident cognitive impairment than for nonusers (odds ratio=2.42; 95% confidence interval=1.17-5.04). CONCLUSION: H2As might be a risk factor for the development of cognitive impairment in African Americans. This finding requires confirmation from future studies.
OBJECTIVES: To evaluate the association between histamine-2 receptor antagonist (H2A) exposure and incident cognitive impairment in a community-based sample of African Americans. DESIGN: Five-year longitudinal observational study. PARTICIPANTS: A sample of 1,558 community-dwelling African Americans aged 65 and older with no baseline cognitive impairment living in Indianapolis, Indiana. OUTCOME MEASURE: Incident cognitive impairment, defined as incident dementia, cognitive impairment without dementia, or poor cognitive performance, as determined using combined cognitive assessments that included the Community Screening Instrument for Dementia, a comprehensive clinical assessment including informant interview, and neuropsychological testing. EXPOSURE: Trained interviewers assessed the use of prescription and over-the-counter H2As using in-home inspection of medications and report of participants and informants. RESULTS: Incident cognitive impairment occurred in 275 (17.7%) participants. After controlling for age, education, baseline cognitive score, the use of anticholinergics, and history of diabetes mellitus and depression, continuous use of H2As was associated with greater risk of incident cognitive impairment than for nonusers (odds ratio=2.42; 95% confidence interval=1.17-5.04). CONCLUSION: H2As might be a risk factor for the development of cognitive impairment in African Americans. This finding requires confirmation from future studies.
Authors: Peter P Zandi; James C Anthony; Kathleen M Hayden; Kala Mehta; Lawrence Mayer; John C S Breitner Journal: Neurology Date: 2002-09-24 Impact factor: 9.910
Authors: Michelle C Carlson; JoAnn T Tschanz; Maria C Norton; Kathleen Welsh-Bohmer; Barbara K Martin; John C S Breitner Journal: Alzheimer Dis Assoc Disord Date: 2002 Jan-Mar Impact factor: 2.703
Authors: Philip D Sloane; Sheryl Zimmerman; Chirayath Suchindran; Peter Reed; Lily Wang; Malaz Boustani; S Sudha Journal: Annu Rev Public Health Date: 2001-10-25 Impact factor: 21.981
Authors: Michael D Murray; Kathleen A Lane; Sujuan Gao; Rebecca M Evans; Frederick W Unverzagt; Kathleen S Hall; Hugh Hendrie Journal: Arch Intern Med Date: 2002-10-14
Authors: Joseph T Hanlon; Lawrence R Landerman; Margaret B Artz; Shelly L Gray; Gerda G Fillenbaum; Kenneth E Schmader Journal: Pharmacoepidemiol Drug Saf Date: 2004-11 Impact factor: 2.890
Authors: Brian C Jacobson; Timothy G Ferris; Tara L Shea; Emmanuel M Mahlis; Thomas H Lee; Timothy C Wang Journal: Am J Gastroenterol Date: 2003-01 Impact factor: 10.864
Authors: Shelly L Gray; Rod Walker; Sascha Dublin; Sebastien Haneuse; Paul K Crane; John C S Breitner; James Bowen; Wayne McCormick; Eric B Larson Journal: J Am Geriatr Soc Date: 2011-02 Impact factor: 5.562
Authors: N L Campbell; M A Boustani; K A Lane; S Gao; H Hendrie; B A Khan; J R Murrell; F W Unverzagt; A Hake; V Smith-Gamble; K Hall Journal: Neurology Date: 2010-07-13 Impact factor: 9.910
Authors: Paul Lochhead; Kaitlin Hagan; Amit D Joshi; Hamed Khalili; Long H Nguyen; Francine Grodstein; Andrew T Chan Journal: Gastroenterology Date: 2017-07-18 Impact factor: 22.682
Authors: Malaz Boustani; Mary Shearer Baker; Noll Campbell; Stephanie Munger; Siu L Hui; Pete Castelluccio; Mark Farber; Oscar Guzman; Adetayo Ademuyiwa; David Miller; Chris Callahan Journal: J Hosp Med Date: 2010-02 Impact factor: 2.960
Authors: Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati Journal: Clin Interv Aging Date: 2009-06-09 Impact factor: 4.458